Quantifying the treatment goals of people recently diagnosed with schizophrenia using best-worst scaling

被引:26
作者
Bridges, John F. P. [1 ]
Beusterien, Kathleen [2 ]
Heres, Stephan [3 ]
Such, Pedro [4 ]
Sanchez-Covisa, Joaquin [5 ]
Nylander, Anna-Greta [4 ]
Chan, Elcie [6 ]
de Jong-Laird, Anne [5 ]
机构
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA
[2] Outcomes Res Strategies Hlth, Albemarle St NW, Washington, DC 20008 USA
[3] Tech Univ Munich, Dept Psychiat & Psychotherapy, Munich, Germany
[4] H Lundbeck A S, Global Med Affairs, Valby, Denmark
[5] Otsuka Pharmaceut Europe Ltd, Med Dept, Wexham, England
[6] Otsuka Pharmaceut Europe Ltd, HEOR Market Access, Wexham, England
来源
PATIENT PREFERENCE AND ADHERENCE | 2018年 / 12卷
关键词
recent-onset schizophrenia; preferences; treatment goals; PREFERENCES; BURDEN; ONSET; ANTIPSYCHOTICS; DISORDERS; BRAIN; AGE;
D O I
10.2147/PPA.S152870
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: This study seeks to quantify the treatment goals of people recently diagnosed with schizophrenia and explore their impact on treatment plan. Methods: People aged 18-35 years with a confirmed diagnosis of schizophrenia within the past 5 years were surveyed in the UK, Germany, and Italy. Treatment goals were assessed via a validated best-worst scaling instrument, where participants evaluated subsets of 13 possible treatment goals identified using a balanced incomplete block design. Participants identified the most and least important goals within each task. Data were also collected on current treatment and preference for daily oral versus long-acting injectable (LAI) treatment. Hierarchical Bayes was used to identify preference weights for the goals, and latent class analysis was used to identify segments of people with similar goals. The segments were compared with the current treatment and preference for oral versus LAI treatment. Results: Across 100 participants, the average age was 26 years, 75% were male and 50% were diagnosed within 2 years ago. Overall, preferences were most favorable for reduced disease symptoms, think clearly, reduced hospitalizations, reduced anxiety, and take care of self. A total of 61% preferred oral medication and 39% LAI. Two groups were identified with different treatment goals; 50% of participants emphasized clinical goals, including reduced disease symptoms (preference weight = 19.7%), reduced hospitalizations (15.5%), and reduced anxiety (10.5%). The other 50% emphasized functional goals, including improved relationships with family/friends (11.4%), increased interest in work (10.6%), experiencing a fuller range of emotions (8.4%), and ability to socialize (7.5%). Those emphasizing functional goals were more likely to be on LAI (44% versus 26%; p=0.059) and preferred LAI (46% versus 32%; p=0.151). Conclusions: People with recent-onset schizophrenia may focus more on clinical goals or functional goals, a discussion of which may help facilitate patient engagement.
引用
收藏
页码:63 / 70
页数:8
相关论文
共 50 条
  • [21] Perceived Importance of Factors in Cannabis Purchase Decisions: A Best-worst Scaling Experiment
    Zhu, Bin
    Guo, Huiying
    Cao, Ying
    An, Ruopeng
    Shi, Yuyan
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2021, 91
  • [22] Position Bias in Best-worst Scaling Surveys: A Case Study on Trust in Institutions
    Campbell, Danny
    Erdem, Seda
    AMERICAN JOURNAL OF AGRICULTURAL ECONOMICS, 2015, 97 (02) : 526 - 545
  • [23] Parent clinical trial priorities for fragile X syndrome: a best-worst scaling
    Turbitt, Erin
    D'Amanda, Celeste
    Hyman, Sarah
    Weber, Jayne Dixon
    Bridges, John F. P.
    Peay, Holly L.
    Biesecker, Barbara B.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2021, 29 (08) : 1245 - 1251
  • [24] Using Best-Worst Scaling to Understand Patient Priorities: A Case Example of Papanicolaou Tests for Homeless Women
    Wittenberg, Eve
    Bharel, Monica
    Bridges, John F. P.
    Ward, Zachary
    Weinreb, Linda
    ANNALS OF FAMILY MEDICINE, 2016, 14 (04) : 359 - 364
  • [25] Comparing Outcomes of a Discrete Choice Experiment and Case 2 Best-Worst Scaling: An Application to Neuromuscular Disease Treatment
    Soekhai, Vikas
    Donkers, Bas
    Johansson, Jennifer Viberg
    Jimenez-Moreno, Cecilia
    Pinto, Cathy Anne
    de Wit, G. Ardine
    de Bekker-Grob, Esther
    PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2023, 16 (03) : 239 - 253
  • [26] Is Best-Worst Scaling Suitable for Health State Valuation? A Comparison with Discrete Choice Experiments
    Krucien, Nicolas
    Watson, Verity
    Ryan, Mandy
    HEALTH ECONOMICS, 2017, 26 (12) : E1 - E16
  • [27] Balancing the nexus of beef sustainability: a best-worst scaling approach to inform policy decisions
    Osman, Eliyasu Y.
    Schroeder, Ted C.
    Lancaster, Phillip A.
    White, Brad J.
    AGRICULTURAL AND RESOURCE ECONOMICS REVIEW, 2024,
  • [28] Will greenhouse concerns impact meat consumption? Best-worst scaling analysis of Australian consumers
    Rolfe, John
    Rajapaksa, Darshana
    De Valck, Jeremy
    Star, Megan
    FOOD QUALITY AND PREFERENCE, 2023, 104
  • [29] A Best-Worst Scaling Experiment to Prioritize Caregiver Concerns About ADHD Medication for Children
    Ross, Melissa
    Bridges, John F. P.
    Ng, Xinyi
    Wagner, Lauren D.
    Frosch, Emily
    Reeves, Gloria
    dosReis, Susan
    PSYCHIATRIC SERVICES, 2015, 66 (02) : 208 - 211
  • [30] Perceived Importance of the Benefits and Harms of Colorectal Cancer Screening: A Best-Worst Scaling Study
    Pluymen, Linda P. M.
    Yebyo, Henock G.
    Stegeman, Inge
    Fransen, Mirjam P.
    Dekker, Evelien
    Brabers, Anne E. M.
    Leeflang, Mariska M. G.
    VALUE IN HEALTH, 2023, 26 (06) : 918 - 924